Optimising treatment use to help prevent disability in multiple sclerosis

Over time, MS leads to significant disability, decreased quality of life and considerable cost to patients and society. It has been established that many disease modifying therapies (DMTs) can reduce long-term disability, especially when commenced early after disease onset. However, many questions remain regarding their optimal use.

Dr Nathaniel Lizak and his team aim to investigate the optimal use of DMTs using large datasets of MS patients from an international registry. They will focus on understanding early markers of treatment success, how to manage failure of high-efficacy DMTs in MS patients, and how to predict and optimally treat progressive MS.

This research aims to improve disability outcomes and quality of life for patients while minimising the cost and risk of long-term therapy.